Cancerorp "Subsidiary OVM Selects CRO for Phase 1 Clinical Trial of Immunotherapy 'OVM-200'"

[Asia Economy Reporter Hyunseok Yoo] Cansellrop announced on the 28th that its subsidiary Oxford Vacmedix (hereinafter OVM) has selected a global contract research organization (CRO) to conduct a Phase 1 clinical trial of the immunotherapy candidate ‘OVM-200’ in the UK.

Cansellrop’s subsidiary OVM (with a 43.46% stake) is an anti-cancer immunovaccine development company spun off from the University of Oxford in the UK. Based on the proprietary Recombinant Overlapping Peptides (ROP) patented technology developed by Dr. Shisong Jiang, a professor at Oxford University and Chief Scientific Officer of OVM, the company is preparing global clinical trials for two candidates, ‘OVM 100’ and ‘OVM 200’.

‘OVM 100’ developed by OVM is an HPV (human papillomavirus) vaccine targeting cervical cancer, and ‘OVM 200’ is a new anti-cancer vaccine targeting survivin, a cancer antigen found in several solid tumors. Both vaccines are being evaluated for efficacy either as monotherapy or in combination with other immunotherapies.

A Cansellrop official said, “This is the first time OVM is conducting ROP clinical trials on humans,” adding, “We plan to conduct the clinical trial in the UK in the second half of this year.”

The CRO selected by OVM was chosen through a competitive bidding process due to its extensive experience in conducting Phase 1 clinical trials and its network and relationships with specialized analytical institutions within the UK. The CRO will collaborate with OVM’s regulatory and manufacturing partners to conduct clinical trials at multiple centers in the UK within 2020. The Phase 1 trial will focus on safety and determining the optimal dosage of ‘OVM-200’ that induces a vaccine immune response.

William Finch, CEO of OVM, said, “The CRO’s extensive early Phase 1 clinical experience will play a crucial role in successfully advancing the clinical trial of ‘OVM-200’,” and expressed hope that the company’s leading cancer treatment ‘OVM-200’ will pass this important clinical stage and provide significant benefits to patients.